| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
| UNI - EN REPORT No | 15 | / | 2019 | ||||||||
| Date of issue: | 2019-04-30 | ||||||||||
| Short name of the issuer | |||||||||||
| KRKA | |||||||||||
| Subject | |||||||||||
| End of litigation relating to esomeprazole product in Denmark | |||||||||||
| Official market - legal basis | |||||||||||
| art. 17. 1 MAR. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| Krka, d. d., Novo mesto (hereinafter referred to as Krka) informs the interested public that its subsidiary Krka Sverige AB, Sweden received the decision of the Danish Supreme Court where the court rejected the application for leave to appeal by AstraZeneca against the decision of the Eastern High Court in Copenhagen. The dispute relating to esomperazole in Denmark has therefore ended. Krka published notices about the litigation in Denmark on 15 December 2010, 11 April 2013, 25 February 2016 and 19 October 2018. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| KRKA, TOVARNA ZDRAVIL D.D. | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| KRKA | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 8501 | Nove Mesto | ||||||||||||
| (post code) | (city) | ||||||||||||
| Smarjeska | 6 | ||||||||||||
| (street) | (number) | ||||||||||||
| +386 7 331 21 11 | +386 7 332 15 37 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nie dotyczy | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2019-04-30 | Jože Colarič | President of the Management Board | |||
